Ginkgo Bioworks Holdings Inc
Company Profile
Business description
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Contact
27 Drydock Avenue
8th Floor
BostonMA02210
USAT: +1 877 422-5362
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
485
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,944.20 | 31.50 | -0.35% |
| CAC 40 | 7,868.05 | 88.65 | -1.11% |
| DAX 40 | 25,319.77 | 302.84 | -1.18% |
| Dow JONES (US) | 51,966.03 | 36.38 | -0.07% |
| FTSE 100 | 10,764.27 | 0.42 | -0.00% |
| HKSE | 23,949.21 | 237.62 | -0.98% |
| NASDAQ | 26,430.89 | 290.85 | 1.11% |
| Nikkei 225 | 64,075.42 | 841.28 | -1.30% |
| NZX 50 Index | 13,631.69 | 20.38 | -0.15% |
| S&P 500 | 7,690.73 | 31.29 | 0.41% |
| S&P/ASX 200 | 8,816.90 | 28.80 | -0.33% |
| SSE Composite Index | 3,732.70 | 1.78 | 0.05% |